Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: THE ANT who wrote (177675)	9/3/2021 7:44:35 AM
From: THE ANT	3 Recommendations Recommended By maceng2 pak73 SirWalterRalegh Respond to of 219500

They will make a small change in the ivermectin molecule or its delivery system and reintroduce at a high price. I carry my ivermectin where ever I go

To: THE ANT who wrote (177675)	9/3/2021 5:29:49 PM
From: flashforward2009	Respond to of 219500

The Ant's Peers.

To: THE ANT who wrote (177675)	9/10/2021 2:25:24 AM
From: Snowshoe	Read Replies (3) \| Respond to of 219500

Results from Brazil... Major study of ivermectin, the anti-vaccine crowd's latest COVID drug, finds 'no effect whatsoever' finance.yahoo.com August 11, 2021 Ivermectin, the latest supposed treatment for COVID-19 being touted by anti-vaccination groups, had "no effect whatsoever" on the disease, according to a large patient study. That's the conclusion of the Together Trial, which has subjected several purported nonvaccine treatments for COVID-19 to carefully designed clinical testing. The trial is supervised by McMaster University in Hamilton, Canada, and conducted in Brazil. One of the trial's principal investigators, Edward Mills of McMaster, presented the results from the ivermectin arms of the study at an Aug. 6 symposium sponsored by the National Institutes of Health. Among the 1,500 patients in the study, he said, ivermectin showed "no effect whatsoever" on the trial's outcome goals — whether patients required extended observation in the emergency room or hospitalization. "In our specific trial," he said, "we do not see the treatment benefit that a lot of the advocates believe should have been" seen. The study's results on ivermectin haven't been formally published or peer-reviewed. Earlier peer-reviewed results from the Together Trial related to the antimalarial drug hydroxychloroquine, which had been touted as a miracle treatment for COVID by then-President Trump, were published in April; they showed no significant therapeutic effect on the virus. The findings on ivermectin are yet another blow for advocates promoting the drug as a magic bullet against COVID-19. Ivermectin was developed as a treatment for parasitical diseases, mostly for veterinarians, though it's also used against some human parasites.